Cardiomyopathy Therapeutics Pipeline Research Report for 2015

Oct 30, 2015, 08:30 ET from Life Science Industry Research

PUNE, India, October 30, 2015 /PRNewswire/ -- adds "Cardiomyopathy - Pipeline Review, H2 2015" therapeutics research report of 119 pages, talking about 16 companies and multiple cardiomyopathy drug profiles to its online library.

This report provides comprehensive information on the therapeutic development for Cardiomyopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects. Complete Cardiomyopathy pipeline report with comprehensive table of contents is available @ .

The report also reviews key players involved in the therapeutic development for Cardiomyopathy and special features on late-stage and discontinued projects. Companies discussed in this Cardiomyopathy - Pipeline Review, H2 2015 report include Array BioPharma Inc., Bioheart, Inc., Gilead Sciences, Inc., Heart Metabolics Limited, Hemostemix Ltd, Kasiak Research Private Limited, miRagen Therapeutics, Inc., MyoKardia, Inc., Neurimmune Holding AG, Nyken BV, Sanofi, Shire Plc, Stemedica Cell Technologies, Inc., Stempeutics Research Private Limited, Torrent Pharmaceuticals Limited, Vericel Corporation and Virocan Therapeutics Private Limited.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are ACP-01, AdipoCell, AmVidcm-008, ARRY-797, binimetinib, CAP-1002, Cyndacel-M, Drugs for Dilated Cardiomyopathy, Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders. Order a purchase copy of this report @ .

Featured News & Press Releases covered by this report include: Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy. Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy. Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T. Nov 20, 2014: University of Pennsylvania Doses First Patient in Phase IIa Clinical Trial Using CardioCell's Stem Cell Therapy to Treat Chronic Heart Failure Due to Non-Ischemic Cardiomyopathy. Nov 12, 2014: Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan. Aug 22, 2014: Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic Dilated Cardiomyopathy. Apr 02, 2014: FDA Grants IND Approval for Phase IIa Clinical Trial Using CardioCell's itMSC Therapy to Treat Dilated Chronic Heart Failure. Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia. Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack. Sep 16, 2013: Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada.

On a related note, offers another research titled Dilated Cardiomyopathy - Pipeline Review, H2 2015 spread across 55 pages, talking about 5 companies, 7 drug profiles and supported with 19 tables and 10 figures. Comprehensive table of contents and more on this research is available at .

Explore more reports on Pharmaceuticals industry at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441

SOURCE Life Science Industry Research